Analysts at StockNews.com began coverage on shares of Lipocine (NASDAQ:LPCN – Get Free Report) in a research report issued on Saturday. The firm set a “sell” rating on the specialty pharmaceutical company’s stock.
Lipocine Stock Up 5.7 %
LPCN opened at $4.81 on Friday. The stock’s fifty day moving average is $4.58 and its two-hundred day moving average is $3.56. The company has a market capitalization of $25.73 million, a P/E ratio of -1.58 and a beta of 1.05. Lipocine has a 52 week low of $2.31 and a 52 week high of $7.15.
Lipocine (NASDAQ:LPCN – Get Free Report) last released its quarterly earnings data on Thursday, March 7th. The specialty pharmaceutical company reported ($0.42) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.11. The firm had revenue of $0.22 million for the quarter. Equities analysts anticipate that Lipocine will post -1.49 earnings per share for the current year.
About Lipocine
Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.
Read More
- Five stocks we like better than Lipocine
- Learn Technical Analysis Skills to Master the Stock Market
- 3 Stocks Leading the U.S. Agriculture Comeback
- 3 Ways To Invest In Coffee, Other Than Drinking It
- How to Use Put Debit Spreads to Profit From Falling Stocks
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.
